Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

17%

2 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

6(54.5%)

Phase 1

3(27.3%)

Phase 3

2(18.2%)

11Total

Phase 2(6)

Phase 1(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT04006145Phase 2Completed

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Role: lead

NCT03566238Phase 3Completed

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Role: lead

NCT04483531Unknown

Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis

Role: lead

NCT03608319Phase 1Completed

Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions

Role: lead

NCT02078856Phase 2Completed

Double-blind, Randomised Study of A3384 in BAM/BAD

Role: lead

NCT01069783Phase 2Completed

Study of A3309 in Patients With Dyslipidemia

Role: lead

NCT03082937Phase 1Completed

An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

Role: lead

NCT02630875Phase 2Completed

A4250, an IBAT Inhibitor in Pediatric Cholestasis

Role: lead

NCT02963077Phase 1Completed

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

Role: lead

NCT04674761Phase 3Completed

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Role: lead

NCT01007123Phase 2Completed

Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation

Role: lead

NCT02360852Phase 2Terminated

IBAT Inhibitor A4250 for Cholestatic Pruritus

Role: collaborator

All 12 trials loaded